In the version of this article initially published online and in print, trastuzumab was incorrectly defined as a tyrosine kinase inhibitor. This error has been corrected for the HTML and PDF versions of the article.
Additional information
The online version of the original article can be found at 10.1038/nrcardio.2015.65
Rights and permissions
About this article
Cite this article
Ewer, M., Ewer, S. Erratum: Cardiotoxicity of anticancer treatments. Nat Rev Cardiol 12, 620 (2015). https://doi.org/10.1038/nrcardio.2015.133
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrcardio.2015.133
This article is cited by
-
Ultrahigh-field cardiovascular magnetic resonance T1 and T2 mapping for the assessment of anthracycline-induced cardiotoxicity in rat models: validation against histopathologic changes
Journal of Cardiovascular Magnetic Resonance (2021)
-
Gene expression profile analysis of gallic acid-induced cell death process
Scientific Reports (2021)
-
Cardiovascular disease and its management in children and adults undergoing hematopoietic stem cell transplantation
Journal of Thrombosis and Thrombolysis (2021)
-
Practical guidance for echocardiography for cancer therapeutics-related cardiac dysfunction
Journal of Echocardiography (2021)
-
Association between clinical risk factors and left ventricular function in patients with breast cancer following chemotherapy
The International Journal of Cardiovascular Imaging (2021)
